MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.110
0.000
0.00%
Closed 16:00 09/23 EDT
OPEN
4.110
PREV CLOSE
4.110
HIGH
4.180
LOW
4.030
VOLUME
37.72K
TURNOVER
--
52 WEEK HIGH
7.85
52 WEEK LOW
3.350
MARKET CAP
112.98M
P/E (TTM)
-159.3023
1D
5D
1M
3M
1Y
5Y
La Jolla Pharmaceutical Names Tony Hodges Chief Medical Officer
MT Newswires · 09/10 11:13
99 Biggest Movers From Yesterday
Gainers
Benzinga · 08/06 09:01
La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 184.62% and 34.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 14:15
BRIEF-La Jolla Pharmaceutical Company Announces Financial Results
reuters.com · 08/05 13:30
La Jolla Pharmaceutical EPS beats by $0.24, beats on revenue
La Jolla Pharmaceutical (NASDAQ:LJPC): Q2 GAAP EPS of $0.11 beats by $0.24. Revenue of $16.06M (+176.4% Y/Y) beats by $4.16M. Press Release
Seekingalpha · 08/05 13:12
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and six months e...
Business Wire · 08/05 12:30
-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Posts Q2 Revenue $16.1M
MT Newswires · 08/05 08:42
--Chardan Suspends Coverage on La Jolla Pharmaceutical at Buy Rating With $15 Price Target
MT Newswires · 08/02 11:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LJPC. Analyze the recent business situations of La Jolla Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LJPC stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 28.12M
% Owned: 102.29%
Shares Outstanding: 27.49M
TypeInstitutionsShares
Increased
11
1.14M
New
8
304.68K
Decreased
31
2.96M
Sold Out
22
709.50K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Director
Kevin Tang
President/Chief Executive Officer/Director
Larry Edwards
Chief Financial Officer
Michael Hearne
Other
Tony Hodges
Independent Director
Laura Douglass
Independent Director
Craig Johnson
Independent Director
David Ramsay
Independent Director
Robert Rosen
No Data
  • All
  • Financials
  • Insiders
More
About LJPC
La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of intra-abdominal infections in patients 18 years of age and older. The LJPC-0118 (I.V. artesunate) is the Company’s investigational product for the treatment of malaria. The LJPC-401 (synthetic human hepcidin) is the Company’s investigational product for the treatment of conditions characterized by iron overload.

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LJPC stock methods without spending real money on the virtual paper trading platform.